Primobolan

Metenolone, sold under the brand name Primobolan, is a synthetic anabolic-androgenic steroid (AAS) of the androstane family and a derivative of dihydrotestosterone (DHT) ^[1]. A double bond in its structure makes it resistant to certain metabolising enzymes, and pharmacologically it is characterised by moderate anabolic (tissue-building) activity together with comparatively weak androgenic (masculinising) activity and no estrogenic action ^[1][2]. It is available as metenolone acetate, taken by mouth, and as metenolone enanthate, given by injection as Primobolan Depot.

The drug dates from the mid-20th century, when it was developed for medical use. Its recognised therapeutic roles have centred on anemia caused by bone marrow failure and on wasting or malnutrition states, and it has historically been used to help promote weight gain. Because it is derived from DHT it is not converted into estrogen, so it does not produce estrogen-related effects, and reviews note that it lacks the marked liver toxicity associated with some other oral steroids ^[1].

Much of metenolone's present-day notoriety comes from non-medical use. It is used off-label and illicitly in bodybuilding and sport to improve physique and performance, often favoured for producing leaner gains with fewer estrogenic side effects. Reviews of anabolic steroid use in athletes report that these drugs can increase strength and lean body mass, but that they also carry a broad range of adverse effects, including virilization in women, acne and body-hair changes, suppression of the body's own testosterone, unfavourable shifts in blood cholesterol, cardiovascular risk and effects on mood and behaviour ^[2][3]. Evidence specific to metenolone is limited, and most modern use occurs without medical supervision.

Metenolone is a controlled substance in many jurisdictions (for example, a Schedule III substance in the United States) and is prohibited in competitive sport by the World Anti-Doping Agency. It is supplied as oral tablets and as an oil-based injection.

Primobolan (methenolone) is a DHT-derived androgen with a mild reputation, but its risks remain real; the oral form is not c17-alpha-alkylated so it is comparatively easy on the liver, while the injectable form spares hepatic tissue entirely. It does not aromatize, so estrogenic effects are minimal, but it still suppresses natural testosterone production and requires recovery support after longer runs. Its DHT backbone drives androgenic effects such as acne and accelerated male-pattern hair loss in predisposed users, and it carries a virilization risk in women even at conservative doses. Like other anabolics it lowers HDL cholesterol and can nudge blood pressure upward, contributing to cardiovascular strain. As a compound not approved for general human use, its safety profile rests largely on pharmacologic reasoning and anecdotal experience rather than controlled trials.